Search User
  • 关于我们

    • 服务范围
    • 服务范围
    • 合作
    • 认可的解决方案提供商
  • 我们的工作

    • 关注领域
    • 气候
    • 水
    • 森林
    • 参与和通知
    • 要求
    • 供应链
    • Public authorities
    • 城市
    • 投资人
    • 政府机构
    • 省/州及地区
  • 为何披露?

    • 作为城市
    • 作为企业
    • As a state or region
    • As a public authority
  • 成为会员

    • 供应链
    • 报告器服务
    • Investors
  • 数据和见解

    • 研究
    • 数据
    • 媒体
    • 博客
指南和调查问卷 联系
地区网站
  • Global
  • 中国
  • Europe
  • India
  • 日本
  • América Latina
  • North America
语言
  • English
  • Español
  • Français
  • 日本語
  • 한국어
  • Português
  • 中文

Welcome to CDP's global website

Please select the site for your country / region to view the most suitable information

  • 中国
  • Europe
  • América Latina
  • India
  • 日本
  • UK
  • North America
  • Stay on global
指南和调查问卷 联系
地区网站
  • Global
  • 中国
  • Europe
  • India
  • 日本
  • América Latina
  • North America
语言
  • English
  • Español
  • Français
  • 日本語
  • 한국어
  • Português
  • 中文
CDP
更多... 更少... Search User 登录 Menu
关于我们 我们的工作 为何披露? 成为会员 数据和见解
  • 关注领域
  • 气候
  • 水
  • 森林
  • 参与和通知
  • 要求
  • 供应链
  • Public authorities
  • 城市
  • 投资人
  • 政府机构
  • 省/州及地区
  • 作为城市
  • 作为企业
  • As a state or region
  • As a public authority
  • 供应链
  • 报告器服务
  • Investors
  • 研究
  • 数据
  • 媒体
  • 博客
  • 服务范围
  • 服务范围
  • 合作
  • 认可的解决方案提供商
Case studies

AstraZeneca: Using purchasing power to accelerate action

AstraZeneca is a global science-led biopharmaceutical company that has been disclosing through CDP for over a decade and has been ranked on the CDP A List for both climate change and water security for six consecutive years.

Since 2015, AstraZeneca has delivered a 59% reduction in their Scope 1 and 2 emissions and in October 2021, AstraZeneca became one of the first companies worldwide to have its emissions reductions targets verified by the Science Based Targets initiative’s new Net-Zero Standard.

With action on Scope 1 and 2 GHG emission reductions well underway, AstraZeneca has accelerated action with its suppliers to reduce Scope 3 emissions, aided by its CDP Supply Chain membership.


Ambition Zero Carbon

AstraZeneca has set an ambitious target to halve their entire value chain footprint (from 2015 baseline) by 2030 leading to a 90% reduction by 2045 (from 2019 baseline).

“Our Scope 3 footprint is more than 20 times greater than our Scope 1 and 2 footprint, and our ambitions will only be achieved through close collaboration with our supply chain partners,” says Jenny Perrie, AstraZeneca’s Scope 3 lead in the Global Procurement team.

“We cannot do this alone; we need to know our suppliers are on the same road to net-zero. So we have set the goal that, by 2025, 95% of our key suppliers and partners should have verified science-based targets, and we are working closely with our sector peers to support the progression to a low carbon economy.”

Perrie emphasized the role of CDP Supply Chain membership in achieving supply chain decarbonization: “We rely on our suppliers’ CDP submissions to gain consistent insight into our Scope 3 emissions. We want our suppliers to use a robust third-party platform so that when our suppliers submit data for AstraZeneca’s Scope 3 programme, it can also be used with their other customers. We recognize the need for common approaches to reporting, to simplify processes and accelerate sustainability. Through CDP Supply Chain membership, we are able to gain confirmation on how our suppliers are progressing with their GHG emissions reduction plans. We then collaborate with our suppliers using the data to create sustainability engagement plans to reach net-zero.”

Perrie continued, “We create opportunities to engage with our suppliers on sustainability, to raise awareness and share lessons learned by AstraZeneca, to reduce GHG emissions across all the procurement categories across our supply chain. In 2021, we invited our top 250 suppliers to participate in the CDP Supply Chain program, and more than 70% of those suppliers disclosed their climate change data, including many suppliers who had never disclosed through CDP before. In 2022, we have stepped up our action further as we recognize the need to accelerate change in this critical decade of delivery against global climate goals. In April 2022, we held a supplier engagement conference ‘Accelerating Sustainability’ for our key suppliers, setting out our clear expectations for 2022. We have now invited over 700 suppliers to report through CDP – nearly three times the number invited last year. The support given by CDP to educate and on-board our suppliers to the Supply Chain program has been essential to achieve this rapid ramp up.”


Purchasing power

“We recognize that every purchasing decision has an impact,” says Perrie, “And we have a responsibility to use our significant purchasing power to support our sustainability goals of developing a healthy society, healthy people and a healthy planet. Through our Positive Sourcing Program, we are embedding sustainability into end-to-end procurement processes, underpinning our delivery of a more sustainable future business,” explains Perrie.

“The sustainable development of our company cannot be separated from that of our suppliers. CDP Supply Chain membership is giving us deeper visibility into our suppliers’ year on year GHG reduction and is an efficient way for us to consistently engage with our suppliers. CDP Supply Chain membership is helping us to drive action towards our 2025, 2030 and longer-term net-zero goals” says Perrie.

Along with disclosure and CDP Supply Chain membership, it is the recognition of the interconnection between all areas of sustainability that drives AstraZeneca’s ambitious social, ethical and environmental sustainability strategy – one of the most innovative in the sector.

CDP

需要帮助?   联系我们。

© 2022 CDP Worldwide
注册慈善机构编号:1122330
增值税登记号码:923257921

一家在英格兰注册的担保有限公司,编号:05013650

  • 认可的解决方案提供商
  • 办公室
  • 员工
  • 受托人、董事会和顾问
  • Cookies
  • 隐私
  • 条款和条件
  • 人才招聘
  • 领英
  • 推特
  • YouTube
  • Facebook
  • Vimeo
我们使用 Cookie来改善您在我们网站上的体验。继续使用我们的网站即表示您接受我们使用Cookie。请参阅我们的Cookie政策和隐私政策以了解详细信息。